Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
70.9M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
37.3M
-
Shares change
-
-1.76M
-
Total reported value, excl. options
-
$117M
-
Value change
-
-$15M
-
Put/Call ratio
-
0.07
-
Number of buys
-
65
-
Number of sells
-
-50
-
Price
-
$3.14
Significant Holders of C4 Therapeutics, Inc. - Common Stock (CCCC) as of Q1 2023
137 filings reported holding CCCC - C4 Therapeutics, Inc. - Common Stock as of Q1 2023.
C4 Therapeutics, Inc. - Common Stock (CCCC) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37.3M shares
of 70.9M outstanding shares and own 52.64% of the company stock.
Largest 10 shareholders include ArrowMark Colorado Holdings LLC (6.38M shares), WASATCH ADVISORS LP (5.72M shares), BlackRock Inc. (3.7M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.88M shares), Soleus Capital Management, L.P. (2.39M shares), VANGUARD GROUP INC (2.11M shares), Bain Capital Life Sciences Investors, LLC (1.64M shares), TCG Crossover Management, LLC (1.25M shares), GEODE CAPITAL MANAGEMENT, LLC (841K shares), and STATE STREET CORP (774K shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.